GlassScriptPhysician profile
Sarah Randrup Proffit
NPI 1104459270
$9,923.31
in general payments reported to CMS, 2019-2025
32 companies · $3,252 in 2025
The $3,252 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,080 · 2022: $615 · 2023: $2,162 · 2024: $2,814 · 2025: $3,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,613 · Travel and Lodging: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,612.87 |
| Travel and Lodging | $614.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,593.56 | 2021-2025 | |
| Enterra Medical, INC. | $1,031.40 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.60 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $636.81 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $597.78 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $561.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $445.02 | 2022-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $398.28 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $346.25 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $331.62 | 2021-2025 | |
| Ardelyx, INC. | $330.39 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $277.82 | 2022-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $218.33 | 2024-2025 | Dupixent |
| Genzyme Corporation | $167.06 | 2024-2025 | |
| Lilly USA, LLC | $164.67 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $148.41 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $147.75 | 2022-2023 | Zeposia |
| Amgen INC. | $113.21 | 2021-2023 | Avsola, Amjevita |
| Novo Nordisk INC | $107.91 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $98.61 | 2021-2023 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $74.39 | 2024 | Iqirvo |
| Pfizer INC. | $73.22 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $58.05 | 2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $55.85 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.41 | 2024 | Cyltezo |
| Sandoz INC. | $41.50 | 2023-2024 | Hyrimoz |
| Exact Sciences Corporation | $31.12 | 2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $29.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.39 | 2022 | |
| Medtronic, INC. | $21.16 | 2023 | Interstim |
| Celltrion USA INC. | $20.81 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Proffit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.